14920-81-1

Basic information

• Product Name: Methyl 2,6-dimethylbenzoate
• Synonyms: 2,6-Dimethylbenzoic acid methyl ester;Methyl 2,6-dimethylbenzoate
• CAS NO: 14920-81-1
• Molecular Formula: C₁₀H₁₂O₂
• Molecular Weight: 164.20
• Mol File: 14920-81-1.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 215.7 °C at 760 mmHg
• Flash Point: 87.3 °C
• Appearance: /
• Density: 1.027 g/cm³
• Vapor Pressure: 0.146mmHg at 25°C
• Refractive Index: 1.508
• Storage Temp.: Room temperature.
• CAS DataBase Reference: Methyl 2,6-dimethylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2,6-dimethylbenzoate(14920-81-1)
• EPA Substance Registry System: Methyl 2,6-dimethylbenzoate(14920-81-1)

Safety Data

• Hazardous Substances Data: 14920-81-1(Hazardous Substances Data)

Usage

General Description

Methyl 2,6-dimethylbenzoate, also known as methyl 2,6-xylidate, is an organic compound with the chemical formula C10H12O2. It is a colorless to pale yellow liquid with a pleasant floral odor, commonly used as a fragrance ingredient in perfumes and personal care products. Methyl 2,6-dimethylbenzoate is a methyl ester derivative of 2,6-dimethylbenzoic acid and is synthesized through the esterification of the acid with methanol. Methyl 2,6-dimethylbenzoate has various industrial applications including its use as a flavoring agent in food and beverages, as well as in the production of pharmaceuticals and agrochemicals. It is also used as a solvent in organic synthesis and as a component in insect repellents.

InChI:InChI=1/C10H12O2/c1-7-5-4-6-8(2)9(7)10(11)12-3/h4-6H,1-3H3

Upstream product

• 67-56-1 methanol 
• 632-46-2 2,6-dimethylbenzoic acid 
• 77-78-1 dimethyl sulfate 
• 21900-37-8 2,6-dimethylbenzoyl chloride 
• 576-26-1 2.6-dimethylphenol 
• 79-37-8 oxalyl dichloride 
• 608-28-6 2,6-dimethyliodobenzene 
• 201230-82-2 carbon monoxide 
• 576-22-7 2-Bromo-m-xylene 
• 26537-19-9 methyl 4-tert-butylbenzoate 
• 75-24-1 trimethylaluminum 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 124-38-9 carbon dioxide 
• 74-88-4 methyl iodide 

Downstream Products

• 2211-84-9 7-methyl-3H-isobenzofuran-1-one 
• 632-46-2 2,6-dimethylbenzoic acid 
• 83194-70-1 methyl 4-hydroxy-2,6-dimethylbenzoate 

Relevant articles and documents

Methyl group transfer upon gas phase decomposition of protonated methyl benzoate and similar compounds

Gas phase decompositions of protonated methyl benzoate and its conjugates have been studied by using electrospray ionization-collision induced dissociation-tandem mass spectrometry. Loss of CO2 molecule, thus transfer of methyl group, has been observed. In order to better understand this process, the theoretical calculations have been performed. For methyl benzoate conjugates, it has been found that position of substituent affects the loss of CO2 molecule, not the electron donor/withdrawing properties of the substituent. Therefore, electrospray ionization-mass spectrometry in positive ion mode may be useful for differentiation of isomers of methyl benzoate conjugates.

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes

GPR52 is an orphan G protein-coupled receptor (GPCR) that has been recently implicated as a potential drug target of Huntington's disease (HD), an incurable monogenic neurodegenerative disorder. In this research, we found that striatal knockdown of GPR52 reduces mHTT levels in adult HdhQ140 mice, validating GPR52 as an HD target. In addition, we discovered a highly potent and specific GPR52 antagonist Comp-43 with an IC50 value of 0.63 μM by a structure-activity relationship (SAR) study. Further studies showed that Comp-43 reduces mHTT levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. Moreover, in vivo study showed that Comp-43 not only reduces mHTT levels but also rescues HD-related phenotypes in HdhQ140 mice. Taken together, our study confirms that inhibition of GPR52 is a promising strategy for HD therapy, and the GPR52 antagonist Comp-43 might serve as a lead compound for further investigation.

Robust synthesis of NIR-emissive P-rhodamine fluorophores

P-Rhodamines were accessed by implementing a robust three step sequence consisting of (i) addition of m-metallated anilines to dichlorophosphine oxides, (ii) selective dibromination, and (iii) cyclization of the diaryllithium reagents derived from the dib

APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF

Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.